Innovent Reports the NMPA’s Approval of Dovbleron (Taletrectinib Adipate Capsule) for Treating ROS1-Positive NSCLC
Shots:
- The NMPA has approved another NDA of Dovbleron (ROS1 tyrosine kinase inhibitor) for treating locally advanced or metastatic ROS1+ NSCLC. It was approved for those with ROS1+ NSCLC previously treated with ROS1 TKIs in Dec 2024
- The approval was supported by pivotal P-II (TRUST-I) study assessing safety, tolerability and efficacy of Dovbleron to treat NSCLC among Chinese population
- Study depicted durable efficacy, with cORR of 91% and intracranial cORR of 88% in ROS1 TKI-naïve patients (n=106); mDoR and mPFS were not achieved after 23.5 months of follow-up. Results were highlighted at ASCO 2024 & published in Journal of Clinical Oncology
Ref: Prnewswire | Image: Innovent
Related News:- Innovent Biologics Collaborates with Roche to Develop IBI3009 for SCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
